Rebalix
SPDR · sheet of 5 September 2026
SPDR · sheet of 5 September 2026ETF sheet · official issuer and register data
State Street® SPDR® MSCI All Country World Investable Market UCITS ETF (Acc)
IMIE · IE00B3YLTY66 · USD · domicile Ireland
Equity · Global · All sizesSFDR art. 6 (inferred)
Index tracked: MSCI ACWI IMI (All Country World Investable Market Index) Index
- TER
- 0.17%+ trans. 0.01%
- Fund size
- 7.6 bn EUR
- Tracking difference
- −0.19%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Physical (optimised)
- Income
- Accumulating
Launch 12 May 2011 · costs from the KID as of 2 Sept 2026 · 6,006 securities held · 10 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 5 Aug 2026
The Shares of the USD Class are issued in U.S. Dollar. Investment objective The objective of the Fund is to track the performance of stock markets in developed and emerging market countries. Index Source: The funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The Prospectus contains a more detailed description of the limited relationship MSCI has with State Street Investment Management…
Performance since series start (in euro) — base 100
16 May 2011 → 3 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +25.5% |
| 3 years | +63.4% |
| 5 years | +70.3% |
| 10 years | +205.1% |
| Since series start | +448.8% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 11.51% | 12.12% | 13.79% |
| Max drawdown | −9.27% | −16.34% | −26.01% |
| Sharpe | 1.76 | 1.31 | 0.62 |
| Sortino | 2.64 | 1.88 | 0.88 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · IMIE · IE00B3YLTY661
RebalixIMIE · IE00B3YLTY66 · sheet of 5 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · declared by the issuer
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +22.20% | +22.06% | +0.14% |
| 2024 | +16.13% | +16.37% | −0.24% |
| 2023 | +21.10% | +21.58% | −0.48% |
| 2022 | −17.52% | −18.40% | +0.88% |
| 2021 | +18.25% | +18.22% | +0.03% |
Holdings
Portfolio as declared by the issuer · 31 Aug 2026 · 6,006 securities · top-10 weight = 21.6%
| Top holdings | Weight |
|---|---|
| 4.3% | |
| 4.1% | |
| 3.0% | |
| 2.1% | |
| 1.7% | |
| 1.7% | |
| 1.4% | |
| 1.3% | |
| 1.1% | |
| 0.9% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
IMIE · Borsa Italiana (ETFplus), Euronext Paris
SPYI · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00B3YLTY66
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00B3YLTY66
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · IMIE · IE00B3YLTY662